Easyhaler® product family
Product info | 19/12/2022EASYHALER®: A CARBON NEUTRAL INHALER RANGE1
The Easyhaler® product family provides a selection of treatment options for both asthma and COPD patients available in a dry powder inhaler form:
Inhaled Corticosteroids
Short acting beta agonist
Long acting beta agonist
Inhaled corticosteroid + long acting beta agonist
COPD = Chronic obstructive pulmonary disease, ICS = Inhaled corticosteroid, SABA = Short acting beta agonist, LABA = Long acting beta agonist, ICS + LABA = Inhaled corticosteroid + long acting beta agonist, FEV1 = Forced expiratory volume in the first second
References:
1. Carbon Neutral Certificate for Easyhaler product range. Orion Pharma. Data on file.
September 2023/RESP-330bbc(5)
Adverse events should be reported. Reporting forms and information
can be found at www.mhra.gov.uk/yellowcard.
Adverse events should also be reported to Orion Pharma (UK) Ltd on 01635 520300.
PRESENTATIONS: AGE: STRENGTHS (ACTUATIONS), PRICE: INDICATIONS: patients not adequately controlled with inhaled corticosteroids and “as needed” inhaled short-acting ß2 adrenoceptor agonists or patients already adequately controlled on both inhaled corticosteroids and long-acting ß2 adrenoceptor agonists Note: Fobumix Easyhaler 80mcg/4.5mcg is not appropriate in patients with severe asthma. |
|
COPD (160/4.5mcg & 320/9mcg only): CONTRAINDICATIONS: UNDESIRABLE EFFECTS: No increased incidence of adverse reactions has been seen following concurrent administration of the two compounds. The most common drug related adverse reactions are pharmacologically predictable side-effects of ß2 agonist therapy, such as tremor and palpitations. These tend to be mild and usually disappear within a few days of treatment. ADVERSE EVENTS: Prescribers should consult the SmPC in relation to other side effects |
||||
|
||||||
PRESENTATIONS: AGE: STRENGTHS (ACTUATIONS), PRICE: INDICATION: |
|
CONTRAINDICATIONS: UNDESIRABLE EFFECTS: ADVERSE EVENTS: Prescribers should consult the SmPC in relation to other side effects. |
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|